Combination chemotherapy with cisplatin

Chemotherapy is one way of mesothelioma treatments that have been shown to improve survival in randomized and controlled trials. The study, published in 2003 by Vogelzang and colleagues compared cisplatin alone with combination chemotherapy of cisplatin and pemetrexed (brand name Alimta) chemotherapy) in patients not receiving chemotherapy for malignant pleural mesothelioma previously and are not candidates for more aggressive "curative" operation. This experiment is the first reported survival benefit of chemotherapy in malignant pleural mesothelioma, showed statistically significant improvement in average survival of 10 months in patients treated with cisplatin alone to 13.3 months in the combination group of patients receiving pemetrexed supplementation with folate and vitamin B12.

Vitamin supplements given to most patients in the trial and related side-effects of pemetrexed was significantly smaller in patients who received pemetrexed when they also receive a daily folate 500mcg oral and intramuscular vitamin B12 1000mcg every 9 weeks compared with patients receiving pemetrexed without vitamin supplementation. Objective response rate increased from 20% in the cisplatin group to 46% in the combination of pemetrexed. Some side effects such as nausea and vomiting, stomatitis, and diarrhea are more common in the combination of pemetrexed group but only affects a minority of patients and the overall combination of pemetrexed and cisplatin was well tolerated when patients received vitamin supplements, good quality of life and pulmonary function tests improved in the combination of pemetrexed. In February 2004, the United States Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma. However, there are still unanswered questions about the optimal use of chemotherapy, including when to start treatment, and the optimal number of cycles to give.

Cisplatin in combination with raltitrexed has demonstrated an improvement in survival similar to that reported for pemetrexed in combination with cisplatin, but raltitrexed is no longer available commercially for this indication. For patients unable to tolerate pemetrexed, cisplatin in combination with gemcitabine or vinorelbine is an alternative, or vinorelbine alone, although survival benefit has not been shown for this drug. For patients who can not be used cisplatin, carboplatin can be substituted but non-random data that have shown lower response rates and high levels of haematological toxicity for carboplatin-based combinations, although the survival rates similar to patients receiving cisplatin.

In January 2009, the U.S. FDA approved the use of conventional therapies like surgery and in combination with radiation or chemotherapy in stage I or II Mesothelioma after research conducted by a national study by Duke University concluded an increase of nearly 50 points at the level of remission.

Xtreme Fat Loss Diet System!

GnRH agonist therapy and premature ovarian failure

In young women who develop breast cancer, ovarian suppression while using triptorelin, a gonadotropin-releasing hormone analog, during the process of chemotherapy proved to reduce the incidence of premature menopause. These findings have been published in the Journal of the American Medical Association in July 2011 and is the result of a study in Italy.

The team of researchers from the Instituto Nazionale per la Ricerca sul Cancro, Genoa, headed by dr. Lucia Del Mastro, underlined that about 6% of women diagnosed with breast cancer under the age of 40 years, and mostly treated with chemotherapy or hormonal therapy. So far, there has been no standard therapies are applied to prevent the occurrence of premature ovarian failure. To investigate the protective effects of temporary ovarian suppression during the treatment of breast cancer, the researchers recruited 281

Potential Metformin as an anti-cancer

Metformin, is one of the medications Diabetes Mellitus (DM) type 2, lately, through several pre-clinical studies are known to have anti-tumor effects. Metformin is the drug of first choice for all patients as DM therapy, unless contraindicated. It turned out that besides the drug is economical drug is also known to have diverse effects pleiotropik, one of which is as anti-cancer properties. As written in the Journal of Clinical Oncology, published in 2009 by Pamela J. Goodwin.

Nevertheless anti-tumor mechanism of metformin is not known with certainty. Several hypothesis: through activation of AMP kinase pathway (AMPK), which is a sensor of cellular energy and potentially a pathway

Clopidogrel therapy Hulu (Upstream) Post-STEMI

The results of a large-scale observational study conducted recently strengthened guidelines updated in Europe and America to recommend the administration of clopidogrel as early as possible post-STEMI (ST-segment elevation myocardial infarction). This finding revealed by dr. David Erlinge and colleagues from Sweden, published in European Heart Journal in early July 2011. These researchers found that clopidogrel therapy upstream (upstream) before patients undergo catheterization associated with a decreased risk of death or myocardial infarction (myocardial infarction, MI) in patients with STEMI who underwent PCI (percutaneous coronary intervention) primer. Clopidogrel, which slow its effects, usually given shortly after the occurrence of STEMI (before primary PCI), although to date there is no definitive evidence regarding this practice.

Addition of dexamethasone to antibiotic therapy

Xtreme Fat Loss Diet System!
The addition of dexamethasone to antibiotic therapy shortens the duration of inpatient care in hospitals on patients suffering from CAP (community-acquired pneumonia) without interference with the immune system. This finding is the result of random double-blind study with placebo control, performed on 304 patients with CAP (age> 18 years) at two teaching hospitals in the Netherlands - 153 patients in the placebo group and 151 patients in the dexamethasone group (infusion of 5 mg / day ). Therapy given for 4 days from hospitalized